Indeed, NSCLC adenocarcinoma patients with tumors harboring KRAS mutations, that account for 25% of the cases, show a shorter median survival (2.41 years) compared to patients candidates to personalized therapies [20, 21]. Here, KRAS is linked to non-small cell lung carcinoma.